Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →Filing growth compares 2021 (6 records) with 2024 (4) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 188 records in scope (CR5), not by the ranked leaders only.
This landscape tracks 188 published records at the intersection of single-use bioreactor hardware and the engineering parameters that govern scaling a process from bench to commercial batch size: tip speed, power density, mixing similarity, oxygen demand and engineering-batch transitions. The search combines disposable bioreactor terminology with scale-up-specific language, then filters to the core bioreactor and mixing IPC classes (C12M1/00, C12M1/12, C12M3/00), so the corpus is narrower and more scale-up-specific than a general single-use bioreactor search would be.
The scope runs from 2015 through the 2026-07-31 data cut-off. Because publication typically lags filing by around 18 months, filing activity in the most recent one to two years is understated in every chart on this page and should not be read as a slowdown on its own.
Two views of the same 188-record corpus: how filing activity has moved year over year, and which IPC subclasses the records actually sit in.
Filings peaked in 2017 at 21 records. The tracked 2021→2024 window moves from 6 to 4, a 33% decline over that span; treat 2025 and 2026 as incomplete rather than as evidence of a further drop.
Every record carries C12M by construction. Mixing and stirring (B01F) reaches 37.2% of the 188 records, well ahead of microorganism and genetic-engineering claims (C12N, 15.4%) and fermentation claims (C12P, 6.4%), which is the clearest signal of where scale-up patenting activity actually concentrates outside the reactor vessel itself.
Shares are the percentage of the 188 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about disposable bioreactor engineering scale-up and every answer comes back with the patent numbers behind it.
Try EurekaThe invention relates to a single-use bioreactor, suitable in particular for use in a bioreactor system, for growing biomass particles, comprising a head plate, a dimensionally stable container and a mixer, wherein the head plate and the container enclose a reaction chamber with the mixer positioned in the reaction chamber, the head plate having an inner side facing towards the reaction chamber, and an outer side which faces away from the reaction chamber and which has a plurality of connectors, and comprising at least one baffle extending from the head plate into the reaction chamber, the baffle having an inner fluid compartment.Filed by Eppendorf AG, published 2015-04-01. The baffle-with-internal-fluid-compartment structure is the narrow, specific feature to watch when assessing freedom to operate around head-plate mixing geometry.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US7384783B2 | Stirred-tank reactor system | 292 |
| 2 | US20050239199A1 | Stirred-tank reactor system | 253 |
| 3 | US20090035856A1 | Continuous perfusion bioreactor system | 174 |
| 4 | US20170349874A1 | Single Use Bioreactor | 135 |
| 5 | WO2007134267A2 | Disposable bioreactor | 84 |
| 6 | US20180010082A1 | Bioreactor With Higher Agitation Rates | 79 |
| 7 | US20110263021A1 | Method and device for industrial biolayer cultivation | 74 |
| 8 | US9109193B2 | Continuous perfusion bioreactor system | 55 |
| 9 | US7901934B2 | Probe connector assembly and method of use | 52 |
| 10 | WO2005104706A2 | Stirred-tank reactor system | 52 |
Citation counts favour older filings simply because they have had more time to accumulate citations inside this searched corpus — read them as a signal of influence on later filers, not as a measure of current importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Read together, the concentration figures, the technology split and the filing trend point to a field where the reactor vessel itself is heavily claimed but the engineering parameters around it are less so.
Five assignees hold 60.6% of the 188 records in scope, and the top ten hold 89.4%. That leaves a long tail of single-filing entrants competing for the remaining slice, which suggests new entrants are more likely to find room by combining bioreactor claims with adjacent process control than by re-filing on the vessel itself.
B01F appears in over a third of the 188 records, far ahead of C12N (15.4%) and C12P (6.4%). Anyone filing on tip speed, power density or mixing similarity should expect to search against this class as closely as C12M itself.
The corpus peaked at 21 filings in 2017. The 2021-to-2024 span the dataset tracks moved from 6 to 4 filings, a 33% decline. The most recent one to two years are still incomplete because of publication lag, so this should be read as a real mid-decade cooling rather than a current collapse.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to disposable bioreactor engineering scale-up, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Baxter International Inc | Baxter Healthcare SA | 22 |
| Baxter International Inc | Hyclone Laboratories Inc | 21 |
| Baxter Healthcare SA | Hyclone Laboratories Inc | 21 |
| ATMI Inc | Takeda Pharmaceutical Co Ltd | 7 |
| Baxter International Inc | OAKLEY ROBERT V | 2 |
| Baxter International Inc | LARSEN JEREMY K | 2 |
| Baxter International Inc | KUNAS KURT T | 2 |
| Baxter International Inc | JONES NEPHI D | 2 |
The corpus records 10 co-assignee pairs, with the strongest links running between a small cluster of legacy Baxter and Hyclone entities — evidence of consolidated ownership history rather than active joint filing today.
The leader holds 34 records against a fifth-place figure of 16 and a tenth-place figure of 9 — a steep drop-off that marks this as a field led by a small number of established bioprocessing and reactor-hardware suppliers rather than a fragmented one.
The top-ranked assignee holds 34 of the 188 records, well ahead of the field. Their filing history spans core bioreactor hardware, which makes them the first reference point for any freedom-to-operate check in this space.
Filing volume steps down to 16 records by fifth place and 9 by tenth, describing a small group of established life-science and bioprocessing suppliers that between them account for the bulk of top-ten share.
Several of the most active historical filers, including the two entities with the strongest co-filing history, show zero filings in the latest tracked year. Given the ~18-month publication lag, this reads more as a reporting gap than as leaders exiting the space.
| Assignee | Recent year | YoY |
|---|---|---|
| Lonza AG | 0 | — |
| Global Life Sciences Solutions USA LLC | 0 | -100% |
| Baxter International Inc | 0 | — |
| Genentech Inc | 0 | — |
| Baxter Healthcare SA | 0 | — |
| Hyclone Laboratories Inc | 0 | — |
| F. Hoffmann-La Roche & Co AG | 0 | — |
| XCELLEREX LLC | 0 | — |
The dataset points to specific next steps depending on whether you are clearing a design, planning a filing, or scouting partners.
With B01F present in 37.2% of records, any new tip-speed or power-density claim should be checked against mixing and stirring filings, not just core bioreactor filings.
Search this space in EurekaThe leader and its closest peers hold 60.6% of the corpus; a filing or momentum change from any of them is the single biggest signal for shifts in this landscape.
Track assignee activity in EurekaOxygen-transfer sensing and scale-down correlation models show thinner filing density than the vessel and mixing core, making them worth a dedicated search before committing to a claim strategy.
Explore white space in EurekaOne assignee leads with 34 of the 188 records in this corpus, roughly double the fifth-place figure of 16. The top five assignees combined hold 60.6% of all records, and the top ten hold 89.4%, so filing activity is concentrated among a small group of established bioprocessing and reactor-hardware suppliers. A long tail of single-filing entrants makes up the remainder of the 52-company ranked list.
Every record in scope carries a core bioreactor classification (C12M), but 37.2% also carry a mixing and stirring classification (B01F), reflecting claims on tip speed, power density and mixing similarity used to justify scale transitions. Smaller but notable shares touch microorganism and genetic engineering (15.4%), fermentation (6.4%), and valve or filtration hardware (around 3-4% each). This spread shows that scale-up patenting extends well beyond the reactor vessel itself into the mixing and fluid-handling hardware around it.
Filing peaked at 21 records in 2017 and has cooled since; the tracked 2021-to-2024 span moved from 6 to 4 filings, a 33% decline. Because publication typically lags filing by about 18 months, the most recent one to two years in any such dataset are undercounted, so a slowdown through 2024 should not be read as the field going quiet today. Anyone tracking this space should expect the 2025-2026 figures to revise upward as more filings publish.
Relative to the dense core of vessel and mixing claims, areas such as oxygen transfer rate sensing in flexible bags, scale-down engineering-batch correlation models, and mixing-similarity computational tools show thinner filing density. These are adjacent to the heavily claimed mixing and stirring space (37.2% of records) but are not yet saturated in the same way. A first claim in these areas would likely centre on a specific sensing method, correlation model, or software-driven scale-transition workflow rather than on the reactor hardware itself.
EP2853584A1, filed by Eppendorf AG and published 2015-04-01, claims a single-use bioreactor with a head plate, dimensionally stable container and mixer, where a baffle extends from the head plate into the reaction chamber and itself contains an internal fluid compartment. The narrow, specific feature is that baffle-with-internal-fluid-compartment structure, not baffles or head-plate mixers in general. Designers working on head-plate mixing geometry should check whether their baffle design carries an internal fluid path before assuming clearance.
The most-cited records in this corpus, including the stirred-tank reactor system filings and the continuous perfusion bioreactor system filing, describe foundational reactor and perfusion architectures that later filings across the field build on. High citation counts mean many subsequent filers have had to reference or distinguish from these claims, which typically signals broad foundational language rather than a narrow feature. Designing around them usually means moving to a materially different mixing or fluid-path architecture rather than a minor dimensional change.
Go past this page: query the whole disposable bioreactor engineering scale-up corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page